The value relevance of accounting variables and analysts’ forecasts: The case of biotechnology firms

Review of Accounting and Finance

Volumn 6, Issue 3, 2007, Pages 233-253

  Mui Siang Tan, Patricia ^a   Yeow Lim, Chee ^a  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

Assets management; Behaviour; Risk analysis; Stock markets

Indexed keywords

EID: 84993081872     PISSN: 14757702     EISSN: 17587700     Source Type: Journal    
DOI: 10.1108/14757700710777992     Document Type: Article

References (32)

1. Ashton, Z. (2000), “A foolish checklist for biotech investing”, available at: TheMotleyFool.com
2. Barron, O., Byard, D., Kile, C. and Riedl, E. (2002), “High-technology intangibles and analysts’ forecasts”, Journal of Accounting Research, Vol. 40, pp. 289-312.
3. Barron, O., Kim, O., Lim, S. and Stevens, D. (1998), “Using analysts’ forecasts to measure properties of analysts’ information environment”, The Accounting Review, Vol. 73, pp. 421-433.
4. Barth, M., Beaver, W. and Landsman, W. (1998), “Relative valuation roles of equity book value and net income as a function of financial health”, Journal of Accounting and Economics, Vol. 25, pp. 1-34.
5. Barth, M., Kasznik, R. and McNichols, M. (2001), “Analyst coverage and intangible assets”, Journal of Accounting Research, Vol. 39, pp. 1-34.
6. Bratic, W., Tilton, P. and Balakrishnan, M. (2000), “Navigating through a biotech valuation”, Journal of Biotechnology in Healthcare Research and Regulation, Vol. 4, pp. 1-6
7. Champion, D. (2001), “Mastering the value chain: an interview with mark levin of millennium pharmaceuticals”, Harvard Business Review, Vol. 79, pp. 108-115.
8. Chan, L., Lakonishok, J. and Sougiannis, T. (2001), “The stock market valuation of research and development expenditures”, Journal of Finance, Vol. LVI, pp. 2431-58.
9. Collins, D., Pincus, M. and Xie, H. (1999), “Equity valuation and negative earnings: the role of book value of equity”, The Accounting Review, Vol. 74, pp. 29-61.
10. Core, J., Guay, W. and Buskirk, A. (2003), “Market valuations in the new economy: an investigation of what has changed”, Journal of Accounting and Economics, Vol. 34, pp. 43-67.
11. Cumming, D. and Macintosh, J. (2000), “The determinants of R&D expenditures: a study of the Canadian biotechnology industry”, Review of Industrial Organization, Vol. 17, pp. 357-370.
12. Dechow, P., Hutton, A. and Sloan, R. (1999), “An empirical assessment of the residual income valuation model”, Journal of Accounting and Economics, Vol. 26, pp. 1-34.
13. Fama, E. and MacBeth, J. (1973), “Risk, return, and equilibrium: empirical tests”, Journal of Political Economy, Vol. 81, pp. 607-636.
14. Hand, J. (2001), “The market valuation of biotechnology firms and biotechnology R&D”, working paper, UNC Chapel Hill.
15. Hand, J. (2003), “Profits, losses, and the nonlinear pricing of internet stocks” in Ed. Hand, J. and Ed. Lev, B. (Eds), Intangible Assets: Values, Measures and Risks, Oxford, New York, NY, pp. 248-268.
16. Hayn, C. (1995), “The information content of losses”, Journal of Accounting and Economics, Vol. 20, pp. 125-153.
17. Kellogg, D. and Charnes, J. (2000), “Real-options valuation for a biotechnology company”, Financial Analysts Journal, Vol. 56, pp. 76-84.
18. Lev, B. (2001), Intangibles: Management, Measurement and Reporting, Brookings Institution., Washington, DC.
19. Lev, B. and Sougiannis, T. (1996), “The capitalization, amortization, and value-relevance of R&D”, Journal of Accounting and Economics, Vol. 21, pp. 107-138.
20. Lipe, R. (1986), “The information contained in the components of earnings”, Journal of Accounting Research, Vol. 24, pp. 37-64.
21. Lo, K. and Lys, T. (2000), “The Ohlson model: contribution to valuation theory, limitations and empirical applications”, Journal of Accounting, Auditing and Finance, Vol. 15, pp. 337-367.
22. McCutchen, W. Jr. and Swamidass, P. (1996), “Effect of R&D expenditures and funding strategies on the market value of biotech firms”, Journal of Engineering and Technology Management, Vol. 12, pp. 287-299.
23. Oliver, R. (2000), The Coming Biotech Age: The Business of Bio-Materials, McGraw-Hill, New York, NY.
24. Trueman, B., Wong, M. and Zhang, X. (2000), “The eyeballs have it: searching for the value in internet stocks”, Journal of Accounting Research, Vol. 38, pp. 137-162.
25. Upton, W. Jr (2003), “Challenges from the new economy for business and financial reporting”, in Ed. Hand, J. and Ed. Lev, B. (Eds), Intangible Assets: Values, Measures and Risks, Oxford, New York, NY, pp. 469-486.
26. Wolff, G. (2001), The Biotech Investor's Bible, John Wiley & Sons, New York, NY.
27. Lang, M. and Lundholm, R. (1996), “Corporate disclosure policy and analyst behavior”, The Accounting Review, Vol. 71, pp. 467-492.
28. Muller, C. (2002), “Strategic management: a tool for growth in the biotechnology sector”, Journal of Commercial Biotechnology, Vol. 8, pp. 226-234.
29. Murphy, M. (2000), Every Investor's Guide to High-Tech Stocks and Mutual Funds, 3rd ed., Broadway Books, New York, NY
30. Ou, J. and Sepe, J. (2002), “Analysts earnings forecasts and the roles of earnings and book value in equity valuation”, Journal of Business Finance & Accounting, Vol. 29, pp. 287-316.
31. Shook, D. (2000), “The slow painful path to payday in genomic stocks”, BusinessWeek Online, 12 June.
32. Vuong, Q. (1989), “Likelihood ratio tests for model selection and non-nested hypotheses”, Econometrica, Vol. 57, pp. 307-334.